Janssen has published a report revealing significant gaps in understanding of blood cancer in individuals in China and Japan, calling for action to improve awareness about the disease in th
England’s National Health Service has lifted restrictions on Janssen’s blood cancer drug Imbruvica (ibrutinib), after a journalist who was suffering from chronic lymphocytic leukaemia (CLL)
Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient adherence and resistance to treatment.
“Adapt or become irrelevant” is the stark message that Janssen’s Company Group Chairman for Europe, Middle East and Africa (EMEA), Kris Sterkens, has for pharma companies that fail to embrace t
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
